Back to results
US 9,541,004 B2Granted
Antagonist antibodies against EphB3
AssigneesNovartis AG, Xoma Technology Ltd.
InventorsLinda Masat, Jeff Hsu
Life of this patent
Estimating the term…
Abstract
EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
Claims25
An isolated antagonist antibody or antigen-binding fragment thereof that comprises the three CDRs of the variable light chain set forth at positions 24 through 35, positions 51 through 57, and positions 90 through 98 of SEQ ID NO 7 and the three CDRs of the variable heavy chain set forth at positions 26 through 35, positions 50 through 67, and positions 99 through 103 of SEQ ID NO:
- 8, wherein the antibody binds the extracellular domain of EphB3 with an affinity (KD) of 10−6 M or less.
Dependencies are inferred from the claim text.